Focus: CRISPR Therapeutics is a Boston-based biotechnology company pioneering CRISPR-Cas9 gene therapy for serious diseases including blood disorders, cancers, and autoimmune conditions. The company operates at clinical-stage with a broad pipeline spanning hematology, oncology, diabetes, and cardiovascular indications.
Profile data last refreshed 15h ago · AI intelligence enriched 22h ago
Stable — net -3 jobs in 30d
3 added, 6 removed. Backfill posture.
Best for early-career scientists and gene therapy specialists seeking pioneering work in a high-stakes, high-impact therapeutic modality with strong visa support.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for CRISPR Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from CRISPR Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? Yahoo Finance
The Best Biotech Stocks to Buy - Morningstar
The Best Biotech Stocks to Buy Morningstar
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? Yahoo Finance
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September - The Globe and Mail
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September The Globe and Mail
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September - AOL.ca
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September AOL.ca
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo